Dermata Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO, CA, 92130
Mailing Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO, CA, 92130
Phone
(858)-223-0882
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 26, 2026 | View on SEC |
| 10-K Annual financial report | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 8-K Current report of material events | February 25, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | February 23, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 18, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 9, 2026 | View on SEC |
| 8-K Current report of material events | February 3, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | February 2, 2026 | View on SEC |
Annual Reports
10-K
March 26, 2026
- Successful Phase 3 clinical trial for XYNGARI acne gel validated Spongilla technology.
- Strategic pivot from high-cost prescription drug development to consumer skincare market.
Material Events
8-K
Financial Distress
February 3, 2026
High Impact
- Dermata Therapeutics dismissed Baker Tilly US, LLP and appointed CBIZ CPAs P.C. as its new independent registered public accounting firm.
- The former auditor, Baker Tilly, had issued 'substantial doubt about the Company’s ability to continue as a going concern' in its 2023 and 2024 audit reports.
Insider Trading
BUY
1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.